Edesa Biotech (EDSA) Change in Receivables (2014 - 2025)
Edesa Biotech (EDSA) posted Change in Receivables of -$217387.0 for Q4 2025, down 160.41% sequentially from $359828.0 in Q3 2025, and down 322.52% YoY from $97692.0 in Q4 2024.
Edesa Biotech (EDSA) Change in Receivables (2014 - 2025) Analysis & Trends
Edesa Biotech has reported Change in Receivables for 12 years, with the latest figure at -$217387.0 in Q4 2025.
- Quarterly Change in Receivables fell 322.52% year-over-year to -$217387.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62908.0 (up 117.56% YoY) and the FY2025 annual result came in at $377987.0, up 206.08% from the prior year.
- Change in Receivables fell to -$217387.0 in Q4 2025 per EDSA's latest filing, from $359828.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $7.6 million in Q1 2021 and troughed at -$3.6 million in Q2 2021.
- A 5-year average of $25955.9 and a median of $9787.5 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2024: Change in Receivables jumped 41930.05% in 2021, then sank 4818.65% in 2024.
- Over 5 years, Change in Receivables stood at $432792.0 in 2021, then soared by 145.01% to $1.1 million in 2022, then tumbled by 90.61% to $99585.0 in 2023, then declined by 1.9% to $97692.0 in 2024, then plunged by 322.52% to -$217387.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$217387.0, $359828.0, and -$110404.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -217,387.00 |
| Dec 31, 2025 | -217,387.00 |
| Sep 30, 2025 | 359,828.00 |
| Sep 30, 2025 | 359,828.00 |
| Jun 30, 2025 | -110,404.00 |
| Jun 30, 2025 | -110,404.00 |
| Mar 31, 2025 | 30,871.00 |
| Mar 31, 2025 | 30,871.00 |
| Dec 31, 2024 | 97,692.00 |
| Dec 31, 2024 | 97,692.00 |
| Sep 30, 2024 | -284,838.00 |
| Sep 30, 2024 | -284,838.00 |
| Jun 30, 2024 | -555,611.00 |
| Jun 30, 2024 | -555,611.00 |
| Mar 31, 2024 | 384,525.00 |
| Mar 31, 2024 | 384,525.00 |
| Dec 31, 2023 | 99,585.00 |
| Dec 31, 2023 | 99,585.00 |
| Sep 30, 2023 | 586,359.00 |
| Sep 30, 2023 | 586,359.00 |